Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04152382 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04152382 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 30 participants.
The verdict
NCT04152382, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is being conducted to determine how safe and how well tolerated LY3462817 is when given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. The study will last up to one year and one month for each participant. As part of protocol addendum, this study is additionally evaluating the safety and tolerability of LY3509754 in participants with psoriasis. Blood tests will be done to check how much LY3509754 is in the bloodstream and how long the body takes to get rid of it. The addendum will last up to 12 weeks for each participant.
Interventions
- DRUG Placebo - IV
- DRUG Placebo - SC
- DRUG LY3462817 - IV
- DRUG LY3462817 - SC
- DRUG LY3509754
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2022-02-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04152382
The ClinicalTrials.gov registry entry for NCT04152382 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo - IV is the first listed.
NCT04152382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04152382 about?
NCT04152382 is a clinical study titled "A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis". This study is being conducted to determine how safe and how well tolerated LY3462817 is when given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. The study will last up to one year and one month...
What is the current status of trial NCT04152382?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-11-20. Estimated completion is 2022-02-09.
What interventions are being tested in trial NCT04152382?
The interventions under investigation include: Placebo - IV (DRUG), Placebo - SC (DRUG), LY3462817 - IV (DRUG), LY3462817 - SC (DRUG), LY3509754 (DRUG).
Who is sponsoring clinical trial NCT04152382?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.